<rt id="yrylp"><nav id="yrylp"></nav></rt>

  • <rp id="yrylp"></rp>
    <rp id="yrylp"><meter id="yrylp"></meter></rp>
      <rt id="yrylp"><nav id="yrylp"><button id="yrylp"></button></nav></rt>
      ×

      Do you want to link to this External Site and leave Amgen.com?

      YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

      ×

      Do you want to link to this External Site and leave Amgen.com?

      YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

      ×

      Do you want to link to this External Site and leave Amgen.com?

      YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

      ×

      Do you want to link to this External Site and leave Amgen.com?

      YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

      ×

       

      Back to Barcelona for ESMO…

      3 Things to Watch from Amgen at the 2019 ESMO Congress

      Amgen is back in Barcelona for the European Society for Medical Oncology (ESMO) to present new data from its oncology pipeline and marketed product portfolio. This follows the release of clinical data at the IASLC 2019 World Conference on Lung Cancer (WCLC) in Spain earlier this month.

      Here are three things to watch from Amgen at the meeting:

      1. New Data from Amgen’s pipeline

        Phase 1 data reported in patients with colorectal cancer (CRC) and appendiceal cancer, and continued response in patients with non-small cell lung cancer (NSCLC).

      2. Abstracts from Amgen's Oncolytic Viral Therapy

        Two late-breaking abstracts featuring Amgen's oncolytic viral therapy, which was the first of its kind approved in the US and Europe.

      3. On display: Bispecific T cell engager (BiTE®) technology and Amgen’s oncology pipeline

        The Amgen Oncology booth will showcase the company’s oncology pipeline and products in an immersive, interactive setting. Alongside the largest pipeline in the Amgen’s history, attendees will discover the BiTE technology targeted immuno-oncology platform. Amgen is advancing more than a dozen BiTE molecules across a broad range of hematologic malignancies and solid tumors, further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential.

      View News Release: Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019

      Follow us on Twitter @AmgenOncology for updates from #ESMO19.

      高清幕免费视频